DexCom, Inc. (NASDAQ:DXCM) Stake Lessened by Oak Thistle LLC

Oak Thistle LLC decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 84.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,223 shares of the medical device company’s stock after selling 34,301 shares during the quarter. Oak Thistle LLC’s holdings in DexCom were worth $484,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of DXCM. Versant Capital Management Inc purchased a new stake in DexCom in the 4th quarter worth approximately $25,000. Riverview Trust Co increased its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom during the third quarter worth $57,000. Covestor Ltd boosted its position in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 335 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in DexCom by 101.9% in the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 898 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.30% of the company’s stock.

DexCom Stock Up 5.5 %

NASDAQ DXCM opened at $84.84 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market cap of $33.14 billion, a PE ratio of 50.80, a PEG ratio of 2.00 and a beta of 1.12. The firm has a 50-day simple moving average of $77.89 and a 200 day simple moving average of $78.41. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent research reports. Oppenheimer cut their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Sanford C. Bernstein boosted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Wells Fargo & Company upped their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Six investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.